Colin Bristow

Stock Analyst at UBS

(1.63)
# 3,309
Out of 5,182 analysts
105
Total ratings
40.32%
Success rate
-5.29%
Average return

Stocks Rated by Colin Bristow

enGene Therapeutics
Nov 12, 2025
Maintains: Neutral
Price Target: $4$10
Current: $6.96
Upside: +43.68%
Vertex Pharmaceuticals
Nov 7, 2025
Maintains: Buy
Price Target: $553$546
Current: $430.14
Upside: +26.94%
Gilead Sciences
Aug 8, 2025
Maintains: Neutral
Price Target: $108$112
Current: $129.26
Upside: -13.35%
PTC Therapeutics
Jul 29, 2025
Maintains: Buy
Price Target: $71$80
Current: $70.26
Upside: +13.86%
Rocket Pharmaceuticals
Jun 17, 2025
Maintains: Buy
Price Target: $12$5
Current: $3.43
Upside: +45.77%
ALX Oncology Holdings
May 21, 2025
Maintains: Buy
Price Target: $1.2$1
Current: $1.64
Upside: -39.02%
Immunovant
Apr 22, 2025
Downgrades: Neutral
Price Target: $38$17
Current: $26.99
Upside: -37.01%
Amgen
Apr 14, 2025
Maintains: Neutral
Price Target: $315$319
Current: $339.57
Upside: -6.06%
Acumen Pharmaceuticals
Mar 28, 2025
Maintains: Buy
Price Target: $6$4
Current: $2.46
Upside: +62.60%
Pfizer
Feb 5, 2025
Maintains: Neutral
Price Target: $29$28
Current: $26.48
Upside: +5.74%
Maintains: Buy
Price Target: $125$120
Current: $110.03
Upside: +9.06%
Maintains: Neutral
Price Target: $234$202
Current: $183.38
Upside: +10.15%
Maintains: Neutral
Price Target: $56$16
Current: $1.06
Upside: +1,409.43%
Maintains: Buy
Price Target: $1,090$1,099
Current: $731.77
Upside: +50.18%
Maintains: Buy
Price Target: $164$167
Current: $21.07
Upside: +692.60%
Maintains: Buy
Price Target: $428$420
Current: $874.00
Upside: -51.95%
Downgrades: Neutral
Price Target: $12$2
Current: $14.67
Upside: -86.37%
Initiates: Buy
Price Target: $18
Current: $1.83
Upside: +883.61%
Maintains: Neutral
Price Target: $154$146
Current: $197.69
Upside: -26.15%
Maintains: Neutral
Price Target: $73$75
Current: $58.26
Upside: +28.73%
Maintains: Buy
Price Target: $64$26
Current: $2.75
Upside: +845.45%
Initiates: Buy
Price Target: $9
Current: $6.20
Upside: +45.16%